ZS Pharma Announces Publication of Results From Phase 3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ZS Pharma Announces Publication of Results From Phase 3 Study of ZS-9 in Patients With Hyperkalemia in the New England Journal of Medicine

COPPELL, Texas, Nov. 21, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq: ZSPH ), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the publication of previously unreleased detailed results from the ZS003 study in the New England Journal of Medicine (NEJM). ZS003 was a Phase 3, 753 patient, multicenter, randomized, double-blind, placebo-controlled trial that assessed the safety and efficacy of ZS-9 (sodium zirconium cyclosilicate) in treating patients with hyperkalemia, a life threatening condition characterized by abnormally high concentrations of potassium in the blood (serum K + ≥5.1 mEq/L).

"We were pleased with the ability of ZS-9 to lower serum potassium in hyperkalemic patients as hyperkalemia is associated with increased mortality in patients with heart failure, chronic kidney disease and diabetes," said the article's lead author, David K. Packham, MBBS(Hons), FRCP, FRACP, MD, from the Royal Melbourne Hospital in Australia. "If ZS-9 receives regulatory approval, I believe it could be a useful tool in the treatment and management of hyperkalemia."

The peer-reviewed study, "Sodium Zirconium Cyclosilicate (ZS-9) in Hyperkalemia," will also appear in the journal's print issue.

About ZS-9's Clinical Development Program

The ZS-9 clinical program is designed to investigate the treatment of acute and chronic hyperkalemia, regardless of underlying cause. ZS Pharma completed its first Phase 3 study, the 753 patient ZS003 study, which showed that ZS-9 reduced serum potassium in hyperkalemic patients to normal levels within the 48-hour Acute Phase and then controlled potassium in the normal range throughout the 12-day Extended Treatment Phase. Results from this study were presented at a late breaking clinical trials session at the American Society of Nephrology meeting in 2013. The Company has also completed its second Phase 3 clinical trial of ZS-9, HARMONIZE, which was a randomized, double-blind, placebo-controlled study that confirmed the positive results observed in ZS003 over a longer treatment period. The HARMONIZE results were recently presented at a late breaking clinical session at the 2014 American Heart Association Scientific Sessions and were published in The Journal of the American Medical Association (JAMA). The Company is conducting additional long-term safety studies, ZS004E and ZS005, designed to evaluate safety and tolerability of ZS-9 in the extended treatment of hyperkalemia with patients receiving at least one year of dosing. The Company plans to file a New Drug Application (NDA) with the United States Food and Drug Administration and a Marketing Authorization Application (MAA) with the European Medicines Agency in the first half of 2015.

About Hyperkalemia

Hyperkalemia, or higher than normal potassium levels (typically defined as a serum potassium level >5 mEq/L), is a potentially life-threatening metabolic condition that can lead to cardiac arrhythmia and sudden cardiac death. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood resulting from the inability of the kidneys to excrete potassium, impairment of mechanisms that transport potassium into cells, or a combination of both factors. The causes of hyperkalemia vary but the most common are chronic kidney disease (CKD), diabetes, heart failure (HF) and side effects from cardio-renal protective drug therapy, such as renin angiotensin aldosterone system (RAAS) inhibitors.

Forward-Looking Statements

ZS Pharma cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward- looking statements include statements regarding the timing of potential regulatory submission and approval of the NDA and/or MAA for ZS-9. Inclusion of forward‐looking statements should not be regarded as a representation by ZS Pharma that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the ZS Pharma business, including, without limitation: the potential for clinical data to not meet pre-specified statistical endpoints, regulatory authorities to not approve an application for ZS-9; analysis of ongoing or future potential clinical trials, including safety-related data, may produce negative or inconclusive results, or may be inconsistent with clinical results achieved to date; the therapeutic and commercial value of ZS-9; and other risks described in ZS Pharma's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ZS Pharma undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ZS Pharma's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission November 10, 2014 and its other reports, which are available from the SEC's website ( http://www.sec.gov ) and on ZS Pharma's website ( http://www.zspharma.com ) under the heading "Investors". All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

ZS Pharma Contacts: Denise Powell (Media) Red House Consulting 510.703.9491 Adam Tomasi (Investors) ZS Pharma 650.458.4100

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 133

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 93

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 183

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
Shenzhen’s APEC Moment Puts Pacific Trade Links in Focus

Updated Category News Views 80

A city that once logged eight stock trades in a day is hosting APEC with a very different kind of ledger in view. Shenzhen Stock Exchange began trial operations on December 1, 1990 with one stock, eight trades and roughly 200,000 yuan in turnover. By the end of September 2026, it had 2,908 listed companies and about 42.43 trillion yuan in combined market value. That is...

Continue Reading
Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 79

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 170

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 91

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Foresite's No. 22 Rank Signals MSSP Growth Momentum

Updated Category News Views 36

Cybersecurity rankings can be a carnival of shiny badges, but No. 22 out of 250 managed security providers is not something a serious buyer should casually brush aside. Foresite Cybersecurity landed there in MSSP Alert's 2026 survey and also made three of the program's new Prestige Top 10 lists: Best Enterprise Focused MSSP, Most Innovative MSSPs, and Fastest Growing...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 90

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
A Hybrid Book Bets on Muscles, Myth, and Machines

Updated Category News Views 66

Few publishing pitches ask readers to carry a barbell into Tartarus, but A R Quigley is plainly not chasing the middle of the bookstore. Doctrina Machina Learning Machine, released by Palmetto Publishing in November 2026, welds together a strength-training guide and an underground military science-fiction war story. That is an odd little contraption, no use pretending...

Continue Reading

Top 5 Most Recently Viewed Articles

Redwire Corp's Exciting NASA Contract Boosts RDW Stock

Updated Category News Views 291

Recent Developments with Redwire Corp (RDW) Redwire Corp shares have recently experienced a notable increase following the announcement of a new contract with NASA. This contract marks an exciting milestone for the company as it seeks to enhance its role in space exploration and biotechnology. Details of the NASA Contract Redwire has been awarded an...

Continue Reading
Exploring the RWA Tokenization and Its Financial Impact

Updated Category News Views 442

CoinEx Research Explores the Evolution of RWA Tokenization CoinEx Research, part of the prominent crypto exchange CoinEx, has launched an insightful two-part report titled “Unlocking the On-Chain Asset Era: A Deep Dive into the Real World Asset (RWA) Tokenization Revolution.” This comprehensive analysis ventures deep into the burgeoning landscape of RWAs, exploring...

Continue Reading
Transforming $1000 into Nearly $10,000: RJF's Growth Journey

Updated Category News Views 213

Unveiling the Growth of Raymond James Financial Inc. Investors often look for robust opportunities that can yield significant returns over time. Raymond James Financial Inc. (NYSE: RJF) has proven to be one such opportunity. Over the past 20 years, RJF has consistently outperformed the market, generating a remarkable average annual return of 12.05%. With a current market...

Continue Reading
Aequum Capital Unlocks $250 Million Financing for Expansion

Updated Category News Views 193

Aequum Capital Unlocks $250 Million Financing for Expansion Aequum Capital Financial, LLC, a rapidly growing specialty finance lender backed by Castlelake, L.P., recently announced a groundbreaking achievement. The company has successfully closed a $250 million debt facility in collaboration with Wells Fargo & Company (NYSE: WFC). This pivotal financing marks a...

Continue Reading
Market Insights: DAX and USD/JPY Trends Worth Noticing

Updated Category News Views 176

Focus on DAX Amid Economic Stagnation The DAX index is currently navigating through a steady phase amid stagnant economic signals. Its performance is largely affected by anticipation regarding upcoming U.S. economic data and evolving conditions within Germany's economy. Stagnation in German GDP Recently, German GDP has shown no growth, remaining at 0% quarter-on-quarter....

Continue Reading